- Title: Subtitle
- SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST)
- Creators
- Brigitte C. Widemann - Center for Cancer Research, National Cancer Institute, Bethesda, MD;Christian Frederick Meyer - Johns Hopkins HospitalGregory Michael Cote - Massachusetts General HospitalRashmi Chugh - Michigan MedicineMohammed M. Milhem - University of IowaBrian Andrew Van Tine - Washington University in St. LouisAeRang Kim - Center for Cancer and Blood DisordersBrian Turpin - Cincinnati Children's Hospital Medical CenterEva Dombi - Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD;Nalini Jayaprakash - National Institutes of HealthScott H. Okuno - Mayo ClinicLee J. Helman - Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD;Ndidi Onwudiwe - Sarcoma Alliance for Research through CollaborationSeth M. Steinberg - National Institutes of HealthDenise K. Reinke - Sarcoma Alliance for Research through CollaborationKaren Cichowski - Brigham and Women's HospitalJohn Peter Perentesis - Cincinnati Children's Hospital Medical Center
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.34(15_suppl), pp.11053-11053
- DOI
- 10.1200/JCO.2016.34.15_suppl.11053
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2016
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984363313902771
Abstract
SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST)
Journal of clinical oncology, Vol.34(15_suppl), pp.11053-11053
05/20/2016
DOI: 10.1200/JCO.2016.34.15_suppl.11053
Details
Metrics
9 Record Views